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Role of Insulin-Like Growth Factor-I in the Autocrine Regulation of
Cell Growth in TT Human Medullary Thyroid Carcinoma Cells

Kuo-Pao P. Yang,* Naguib A. Samaan,* Yi-Fan Liang,* and Socorro G. Castillo'

Since the TT human medullary thyroid carcinoma cell line required fewer exogenous growth factors
(serum), we investigated whether this line has an autocrine mechanism by examining the effects of
antibodies directed toward insulin-like growth factor I (IGF-I) and its receptor on TT cell growth in
serum-free conditions. Treating cells with anti-IGF-I antibody for four days reduced the cell number
by more than 50% compared with a nonimmune IgG control. Furthermore, a monoclonal antibody to
the IGF-I receptor suppressed DNA synthesis when determined by a f^Hfthymidine incorporation
assay. E.xogenous IGF-I (20 ng/mL) stimulated fHjthymidine incorporation in serum-free medium;
approximately 70% of the IGF-I-induced stimulation was blocked by the presence of the receptor
antibody. Treating TT cells with IGF-I for 48 hours increased the cell population in the S phase by
62% when analyzed by flow cytometry. These data suggest that TT cells might respond to endogenously produced IGF-I and therefore provide an in vitro model for autocrine regulation of human
tumor cell growth by IGF-I. (Henry Ford Hosp MedJ 1992;40:293-5)

M

any types of cancer cells produce polypeptide growth factors and often the same cells have functional receptors for
the factors they release (1,2). This autocrine mechanism enables
the cells to grow autonomously and may play a role in cellular
transformation and in the continued proliferation of neoplastic
cells.
Insulin-like growth factors (IGF-I and IGF-II)—mitogenic
polypeptides with stractural similarity to insulin (3,4)—have
regulated in vitro cell growth for many human tumor types
through autocrine and paracrine mechanisms (5). However, the
importance of IGFs in the control of cell proliferation of human
medullary thyroid carcinoma (MTC) cells remains unclear.
To examine the role of IGFs, we chose an established human
MTC cell line, TT, which has maintained the morphological
characteristics of MTC and the neuroendocrine properties of
thyroid C-cells (6,7). The cell line has an abnormal karyotype
with multiple rearranged chromosomes, including chromosomes 11 and 12 (8) where the IGF-I and IGF-II genes are located (9). Herein we examine the effects of a polyclonal antibody towards IGF-I and of a monoclonal antibody towards the
IGF-I receptor on TT cell proliferation.

Materials and Methods
Cell culture and antibodies
The TT human MTC cell line was provided by Dr. Robert
Gagel (M.D. Anderson Cancer Center, Houston, TX) and was
initially established by Dr. Leong (Roswell Park Memorial Institute, Buffalo, NY). Cells were routinely passaged in RPMI1640 supplemented with 10% fetal calf serum (FCS) and 2 mM
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glutamine. Human recombinant IGF-I and the rabbit polyclonal
antibody to IGF-I were obtained from Amgen Biologicals
(Thousand Oaks, CA). alRj, a mouse monoclonal IgG, against
the IGF-I receptor, was purchased from Oncogene Science, Inc.
(Manhasset, NY). Nonimmune rabbit IgG was obtained from
Zymed Laboratory (South San Francisco, CA). A mouse monoclonal IgG, against carcinoembryonic antigen (anti-CEA IgG,),
FPI-031490, was a gift from Dr. Chen (M.D. Anderson Cancer
Center, Houston, TX).
Cell proliferation assays
TT cells were plated in 96-well dishes at a density of 5 x 10^
cells/well with RPMI medium containing 10% FCS and 2 mM
glutamine. After 48 hours, cells were placed in seram-free medium (RPMI medium containing 0.3% bovine seram albumin
and 2 mM glutamine) for another 24 hours. Triplicate cells were
then fed with seram-free medium or media containing different
amounts of FCS. The spent media were replaced with fresh media after two days. For proliferation-inhibition experiments, the
antibody to IGF-I or control IgG was added to seram-free medium 24 hours after seram starvation. The antibody-containing
media were refreshed after two days. Cell counts were determined by a Coulter counter (Coulter Electronics, Inc., Hialeah,
FL) after suspending the cells with trypsin-EDTA.
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propidium iodine. About 5,000 cells were analyzed for the cellcycle distribution on a FACSTAR-PLUS (Becton Dickinson,
Mountain View, CA) cell sorter equipped with an argon laser
operating at 488 nm. DNA profiles were analyzed by software
provided by Becton Dickinson.

/

Results

pH]Thymidine incorporation studies
Cells were plated in the regular growth medium into 96-well
dishes (5 x lO'^/well) and maintained for tfu-ee days. After removing the medium, the monolayers were washed once with serum-free medium and incubated for 48 hours, with one additional change of the medium at 24 hours. The medium was replaced with fresh serum-free medium, and either the vehicle
(control) or test agents were added to the wells. After incubation
for 17 hours, [methyl-^H]thymidine (5 Ci/mmoL, final concentration 2 |a,Ci/mL) was added, and the cells were incubated for an
additional three hours. The labeling was terminated by removing the medium, washing once with ice-cold serum-free medium, and washing twice with 10% trichloroactic acid. The cellassociated radioactivity was recovered by solubilization with
0.5 N NaOH, neutralized with HCl, and counted in a scintillation spectrometer.

Although TT cells are normally grown in RPMI medium
containing 10% FCS, they also proliferated in medium containing a reduced amount of serum (1%) or even in seram-free medium, although with slower growth rates (Fig 1). Under seramfree conditions, the anti-IGF-I antibody inhibited cell growth
more than 50% after four days in culture, suggesting that TT
cells proliferated in serum-free conditions in response, at least
partially, to endogenously secreted IGF-I or IGF-I-related substances.
Like other polypeptide hormones and growth factors, the biological activities of IGF-I are mediated by specific receptors on
the cell surface. We therefore examined the effect of the IGF-I
receptor blockade in serum-free medium using a monoclonal
antibody, alRj, that specifically blocks IGF-I receptor binding
(10,11). Fig 2 shows the alRj-induced inhibition of [-''H]thymidine incorporation in TT cells. At a concentration of 15 (rg/
mL, alR, inhibited [-''H] thymidine incorporation by 45% compared with the anti-CEA IgG, control. The inhibition of alRj
was dose-dependent (data not shown).
To confirm the specificity of the inhibitory effect of alR,, we
determined the stimulatory effect of exogenous IGF-I in seramfree medium in the presence or absence of the receptor antibody.
IGF-I at a 20 ng/mL concentration stimulated DNA synthesis
([-""Hlthymidine incorporation) 1.6-fold more than the basal
level (Fig 2). More than two-thirds of the IGF-I-induced mitogenic effect was suppressed by the monoclonal antibody against
the IGF-I receptor, whereas the control IgG, had no significant
effect.
Since it has been reported in fibroblasts that IGF-I is required
for cells to progress through G, to the S phase (12), we also determined whether the mitogenic effect of IGF-I was associated
with IGF-I-induced alterations of the cell cycle distribution in
the TT cell line. The cells were grown in serum-free conditions
in the presence or absence of IGF-I; DNA histograms of the
treated and untreated controls were then analyzed by flow cytometry. The data revealed that treatment with 20 ng/mL IGF-I
for 48 hours increased the cell population in the S phase by 62%
compared with the untreated control (8.8 ± 0.7% versus 5.4 ±
0.4%).

Flow-cytometric analysis
TT cells were first plated in the regular medium and maintained at 37 °C for 24 hours. After removing the medium, the
cells were washed once with serum-free medium, incubated for
an additional 24 hours, and treated with IGF-I (20 ng/mL) in refreshed seram-free medium for 48 hours. For flow-cytometric
analysis, cells were harvested in single-cell suspensions,
washed with saline, and fixed in 70% ice-cold ethanol. The
fixed cells were stained in phosphate-buffered saline containing
0.05% Nonidet P-40,0.2 mg/inL ribonuclease A, and 10 mg/mL

Our initial observations that the TT cell line needed little or
no seram in culture prompted us to investigate whether these
cells possessed an autonomous growth system. An anti-lGF-I
antibody alone suppressed cell proliferation more than 50% tn
seram-free conditions, leading us to believe that TT cells may
produce IGF-I, which in tura stimulated cell growth. The role of
endogenously secreted IGF-I in autocrine regulation was again
demonstrated by the inhibition of basal DNA synthesis by die
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Fig I—Proliferation of TT cells in serum-containing, serumfree, and serum-free plus anti-IGF-I antibody media. Cells were
grown in regular growth medium for two days and then placed
into serum-free medium. After 24 hours (on day 0), the serumfree medium was replaced with fresh serum-ft-ee medium (indicated by solid triangles) or medium containing 1% (open circles) or 10% (solid circles) fetal calf serum. For proliferationinhibition experiments, the antibody to IGF-I (open squares) or
control IgG (solid squares) was added to serum-free medium on
day 0. The spent media and antibody-containing media were refreshed on day 2. Cell counts were performed on days 0,2, and
4. The figure shows the mean of triplicate determinations ofa
representative experiment.
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Discussion
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antibody-mediated IGF-I receptor blockade. This inhibitory effect was specifically associated with IGF-I receptor inhibition
and was not due to nonspecific toxic effects of the antibody
because simultaneous addition of IGF-I under serum-free conditions reversed the alR^ antibody-induced suppression of
[^HJthymidine incorporation. The presence of functional IGF-I
receptor in TT cells was supported by the fact that exogenous
IGF-I, at physiological concentrations, stimulated [^H]thymidine incorporation, and the apparent IGF-I-induced mitogenic effect could be suppressed by simultaneous addition of the receptor antibody. IGF-I increased the cell population in the S phase,
further demonstrating IGF-I's growth-promoting effect. Taken
together, these data suggest that activated pathways for production of IGF-I and expression of the IGF-I receptor may have
been turaed on in TT cells. Identification of quantities of IGF-I
in the conditioned medium and the IGF-I receptor on TT cell
surfaces that are high enough to suggest gene activation is required to confirm this notion. These studies are currently under
way.
Since the IGF-I antibody alone could suppress more than
50% of the basal growth of this cell line, IGF-I must be one of
the major growth factors involved in the regulation of TT cell
proliferation. Whether stmcturally related IGF-II and other unrelated growth factors act in concert with or opposition to IGF-I
in the autocrine regulation of TT proliferation is also being investigated in our laboratory.
In conclusion, this study suggests that TT cells might respond
to endogenously produced IGF-I and therefore provide an in
vitro model for autocrine regulation of human tumor cell growth
by IGF-I.
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